SciSparc secures European patent for antimicrobial method By Investing.com

TEL AVIV – SciSparc Ltd. (NASDAQ:SPRC), a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, has been granted a European patent titled “Compositions and Methods of Potentiating Antimicrobials.” This follows a similar patent previously issued by the United States Patent and Trademark Office.

The patent underlines the company’s strategy to strengthen its intellectual property portfolio globally. The newly granted patent covers pharmaceutical compositions that combine antibiotics with cannabinoids, and potentially N-acylethanolamines, aiming to enhance the effectiveness of antimicrobials and reduce their side effects.

This approach is particularly relevant in addressing the challenges of antimicrobial and antibiotic resistance, which the World Health Organization has identified as a significant threat.

SciSparc has been proactive in securing patents, with recent grants in Canada and Europe since the beginning of the year, reflecting its commitment to global innovation protection. The company’s portfolio now includes a range of patents across key markets such as the United States, Europe, Japan, Australia, and Israel, encompassing nine patent families and two trademarks.

The company’s focus is on cannabinoid-based pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette Syndrome, Alzheimer’s disease, pain, ASD, and status epilepticus. Additionally, SciSparc holds a controlling interest in a subsidiary selling hemp seed oil products on Amazon.com (NASDAQ:).

This patent grant bolsters SciSparc’s competitive position and is part of its continuous effort to protect its core technologies. The information about the patent grant is based on a press release statement from SciSparc Ltd.

InvestingPro Insights

SciSparc Ltd. (NASDAQ:SPRC) has recently made headlines with its strategic move to secure a European patent for its innovative pharmaceutical compositions. As investors look into the company’s financial health and market performance, certain metrics and InvestingPro Tips provide a deeper understanding of SciSparc’s current position.

InvestingPro Data highlights that SciSparc has a market capitalization of $2.84 million, indicating its size within the pharmaceutical sector. The company’s revenue for the last twelve months as of Q4 2023 stands at $2.88 million, with a significant growth rate of 113.73%.

Still, it is important to note that the quarterly revenue growth for Q1 2023 shows a decrease of 32.67%. These figures suggest that while the company has experienced a notable yearly increase, it faces challenges maintaining that momentum into the current year.

The financial strength of SciSparc is further illuminated by its cash position, as one of the InvestingPro Tips indicates that the company holds more cash than debt on its balance sheet. This provides SciSparc with a level of financial stability and flexibility, which is crucial for a clinical-stage pharmaceutical company facing the uncertainties of drug development and regulatory approval processes.

On the other hand, the stock’s performance presents a different picture. It has taken significant hits over various time frames, with a 1-month price total return of -25.0% and a staggering 6-month price total return of -86.56%. The stock’s current price is just 4.44% of its 52-week high, and the price at the previous close was $1.05. These figures reveal that investors may have concerns about the company’s future prospects, despite the recent patent grant.

For those considering an investment in SciSparc, an additional 12 InvestingPro Tips are available, which could provide more nuanced insights into the company’s potential. To explore these tips and gain a comprehensive analysis, readers can visit https://www.investing.com/pro/SPRC and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. This exclusive offer may equip investors with valuable information to make informed decisions regarding SciSparc and its place in their investment portfolio.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.